Since 2012, Lizza Hendriks works as a pulmonologist, specialised in lung cancer in Maastricht University Medical Center+, Maastricht, The Netherlands. Her main interest is brain metastases in lung cancer patients and in 2016 she obtained a PhD on this topic. As of 2019, she leads the clinical lung cancer research department in the hospital. Dr. Hendriks is (sub)-investigator in several phase II and III clinical trials, mainly focusing on (locally) advanced NSCLC and SCLC, and treatments with targeted treatment and immunotherapy. Dr. Hendriks is program leader of the Innovative Cancer Diagnostics Therapy group at GROW - School for Oncology and Developmental Biology at the Maastricht University. She is an active member of the NVALT (and oncology subgroup), ERS, IASLC, ASCO, ESMO, EORTC lung cancer group and NRS, and she is chair of the metastatic NSCLC, systemic therapy group of the EORTC lung cancer group. She is a member of several guideline committees (Dutch: brain metastases, leptomeningeal metastases and NSCLC guidelines; ESMO: SCLC guideline) and is a speaker on and program committee member of several (inter)national conferences. She is also member of the Young Academy of the Royal Netherlands Academy of Arts and Sciences.